The role of the IGF axis in bladder cancer progression
Dr C Perks, Prof J Holly
Applications accepted all year round
Bladder cancer is the 4 th most common in cancer in males and 13 th in women with a lifetime risk of 1:40 for men and 1:110 for women; the ten year survival rates are only approx.
Defining how cancer cells acquire resistance to microtubule-based drugs
Institute of Cell Biology
Dr J Welburn, Dr N Carragher
13 December 2018
Taxol (paclitaxel) is a major drug used in the treatment of solid cancers (breast, lung, ovarian, bladder). However, resistance to taxol arises regularly and thus it is critical to find ways to circumvent this resistance.